Q2 FY26 results: revenue up 116% YoY, PAT jumps 259%

Revenue Growth 20pctPat Growth 25pctNegative Operating CashflowResults View source PDF Explain this filing

AHCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.0%Reaction day

₹14.31

prior close

₹14.65

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+2.2% vs market

Pharmaceuticals peers, median of 157sector-0.2%+2.2% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.0

10m

+1.0

15m

+0.3

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.0-0.3+2.2-0.2+2.2

Next day

-1.6+0.7-2.3+0.5-2.1

+0.2+0.6-0.4+0.6-0.4

-0.8+0.5-1.3+0.5-1.3

+4.8+1.1+3.7+0.2+4.6

+10.1+0.3+9.9-0.6+10.8

+9.3-0.2+9.5-1.1+10.4

15d

+10.0-2.2+12.2-2.1+12.1

-1.3-4.9+3.6-3.2+1.9

-5.0-7.5+2.5-5.9+1.0

-14.0-4.8-9.3-6.4-7.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anlon Healthcare reported Q2 FY26 revenue of Rs 5,220 lakhs, up 116% from Rs 2,417 lakhs YoY. PAT surged 259% to Rs 932 lakhs. H1 FY26 revenue rose 38% to Rs 8,550 lakhs with PAT at Rs 1,286 lakhs (up 102%). The company recently listed on NSE and BSE on September 3, 2025 after raising Rs 121 crore via IPO. Total equity surged from Rs 8,042 lakhs to Rs 21,432 lakhs on fresh equity infusion. Cash from operations turned negative, driven mainly by a sharp rise in trade receivables and inventories. One investor complaint remains unresolved.

Likely market impact

Strong post-listing debut quarter with triple-digit profit growth, though negative operating cashflow and rising working capital need monitoring.